WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer
Qianghua Zhou, Xu Chen, Haixia He, Shengmeng Peng, Yangjie Zhang, Jingtong Zhang, Liang Cheng, Sen Liu, Ming Huang, Ruihui Xie, Tianxin Lin, Jian Huang
Abstract
These data revealed that targeting WDR5 suppressed proliferation, enhanced apoptosis, chemosensitivity to cisplatin and immunotherapy in PCa. Therefore, our findings provide insight into OICR-9429 is a multi-potency and promising therapy drug, which improves the antitumor effect of cisplatin or immunotherapy in PCa.
Topics & Concepts
Cancer researchChromatin immunoprecipitationProstate cancerBiologyH3K4me3Chromatin remodelingHistoneCisplatinIn vivoGene knockdownApoptosisCancerGene expressionGeneChemotherapyBiochemistryGeneticsBiotechnologyPromoterProstate Cancer Treatment and ResearchCancer Immunotherapy and BiomarkersRNA Research and Splicing